Parnell Pharmaceuticals Holdings Ltd. (NasdaqGM:PARN) announced that it has entered into a securities purchase agreement for a private placement of 175,000 ordinary shares at $3.50 per share for gross proceeds of $612,500 with new accredited investor, Lincoln Park Capital Fund, a fund managed by Lincoln Park Capital on February 23, 2016. The company will also issue warrants to purchase up to an additional 150,000 ordinary shares for a purchase price of $5 per share for a period of six month and one day anniversary of the issuance date. The company will issue the securities pursuant to exemption provided under Regulation D. The company will pay non-accountable fee equal to $22,500.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 29 | |
-9.30% | 6.48B | |
+24.75% | 3.7B | |
-3.20% | 3.1B | |
+2.53% | 1.44B | |
-15.13% | 1.37B | |
-25.63% | 1.24B | |
-6.64% | 1.19B | |
-10.84% | 1.17B | |
-.--% | 1.05B |
- Stock Market
- Equities
- PARNF Stock
- News Parnell Pharmaceuticals Holdings Ltd
- Parnell Pharmaceuticals Holdings Ltd. announced that it expects to receive $0.61 million in funding from Lincoln Park Capital